Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cholesstrinol lawsuit

This article was originally published in The Tan Sheet

Executive Summary

SourceOne Global Partners files a lawsuit against KGK Synergize following a dispute about intellectual property originally licensed to SourceOne for KGK's Sytrinol heart health supplement. The complaint filed Dec. 29 in U.S. District Court for the Northern District of Illinois, Eastern Division, says SourceOne's Cholesstrinol supplements do not infringe KGK's patent, and alleges that KGK made false and derogatory statements about SourceOne and its products. In a Jan. 7 statement, London, Ontario-based KGK says the lawsuit is SourceOne's "effort to sidetrack our termination of their license and our letter pointedly telling them to cease and desist their infringement." Chicago-based SourceOne launched the Cholesstrinol line in February 2008 (1"The Tan Sheet" March 17, 2008, p. 14)
Advertisement

Related Content

New Products In Brief
New Products In Brief

Topics

Advertisement
UsernamePublicRestriction

Register

PS102529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel